2-氨氧基乙醇 | 3279-95-6

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氨氧基乙醇
• 中文别名: 2-氨基氧基乙醇；2-(氨氧基)乙醇
• 英文名称: O-(2-Hydroxyethyl)hydroxylamine
• 英文别名: 2-aminooxyethanol；2-(Aminooxy)ethanol
• CAS: 3279-95-6
• 化学式: C₂H₇NO₂
• mdl: MFCD00517034
• 分子量: 77.0831
• InChiKey: WWWTWPXKLJTKPM-UHFFFAOYSA-N

物化性质

• 沸点：
  61-62℃ (1 Torr)
• 密度：
  1.1462 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  5
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  3
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P403+P235
• 危险品运输编号：
  1993
• 危险性描述：
  H225
• 储存条件：
  | 温度范围：2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Aminooxy)ethanol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Aminooxy)ethanol
CAS number: 3279-95-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C2H7NO2
Molecular weight: 77.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨氧基乙醇 、 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以60%的产率得到2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide
  参考文献：
  名称：

  氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途

  摘要：

  本发明涉及氮杂双环[3.2.1]辛烷类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的氮杂双环[3.2.1]辛烷类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是FXR激动剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。

  公开号：

  CN110357875B
• 作为产物：
  描述：

  2-[(isopropylideneamino)oxy]-ethanol 在 盐酸 作用下， 生成 2-氨氧基乙醇
  参考文献：
  名称：

  氨基酸及相关化合物的合成和γ-氨基丁酸转氨酶抑制。

  摘要：

  DOI：

  10.1021/jm01238a006
• 作为试剂：
  描述：

  3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-5-vinylbenzoic acid 、 2-氨氧基乙醇 在 2-氨氧基乙醇 作用下， 以91的产率得到3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-vinylbenzamide
  参考文献：
  名称：

  Bioorganic & Medicinal Chemistry Letters 2011, 21, 1795-1801

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION DANS LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：MUTABILIS

  公开号：WO2018060481A1

  公开（公告）日：2018-04-05

  The invention relates to a compound of formula (I) and a racemate, an enantiomer, a diastereoisomer, a geometric isomer or a pharmaceutically acceptable salt thereof, and its use as antibacterial agent.

  这项发明涉及一种式(I)的化合物及其外消旋体、对映体、二对映异构体、几何异构体或药学上可接受的盐，并且其作为抗菌剂的用途。
• [EN] TOPICAL FORMULATIONS<br/>[FR] FORMULATIONS TOPIQUES
  申请人：NFLECTION THERAPEUTICS INC

  公开号：WO2020106304A1

  公开（公告）日：2020-05-28

  Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

  本文提供了用于治疗皮肤疾病的凝胶局部制剂，包括：a) MEK抑制剂；b) 一种或多种有机溶剂，其重量约为70%至99%；和c) 凝胶剂；其中所述一种或多种有机溶剂选自以下组：C2-6醇，C2-6烷基二醇，二-(C2-6烷基)二醇，聚乙二醇，C1-3烷基-(OCH2CH2)1-5-OH，二甲基亚砜，乙酸乙酯，丙酮，N-甲基吡咯烷酮，苯甲醇，甘油和一种油；所述凝胶剂为分子量范围约为40,000 Da至2,500,000 Da的羟丙基纤维素；其中所述凝胶局部制剂的粘度为1至25,000 cps；当存在DMSO时，将DMSO与至少一种其他所述有机溶剂结合，使DMSO的重量不超过50%。
• [EN] 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE<br/>[FR] 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRADINES SUBSTITUÉES EN POSITION 6 À ACTIVITÉ TYROSINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2013038362A1

  公开（公告）日：2013-03-21

  The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式(I)化合物及其盐：公式(I)其中的取代基如说明书中所定义；用于治疗人体或动物体的公式(I)化合物，特别是针对c-Met酪氨酸激酶介导的疾病或状况；使用公式(I)化合物来制造治疗此类疾病的药物；包含公式(I)化合物的药物组合物，可选地与联合用药伙伴一起使用，以及制备公式(I)化合物的方法。
• [EN] 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS<br/>[FR] DERIVES DE 4-[PHENYLAMINO (SUBSTITUE)]-2-PYRIDONE A SUBSTITUTION EN 5 EN TANT QU'INHIBITEURS DE LA MEK
  申请人：WARNER LAMBERT CO

  公开号：WO2005000818A1

  公开（公告）日：2005-01-06

  The present invention relates to 5-substituted-4-(substituted) phenylamino-2-pyridone derivatives of formula (I), pharmaceutical compositions and methods of use thereof as MEK inhibitors. Formula (I) wherein W is formula (II), formula (III), formula (IV), or formula (V); and R1-5 and Z are as defined in the claims.

  本发明涉及公式（I）的5-取代-4-(取代)苯胺基-2-吡啶酮衍生物，以及作为MEK抑制剂的药物组合物和使用方法。其中，公式（I）中W为公式（II）、公式（III）、公式（IV）或公式（V）；R1-5和Z如权利要求中所定义。
• [EN] 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF<br/>[FR] UTILISATION DE DÉRIVÉS 2-PHÉNYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE COMME INHIBITEURS DE PHOSPHODIESTÉRASE ET LEURS UTILISATIONS
  申请人：TOPADUR PHARMA AG

  公开号：WO2017085056A1

  公开（公告）日：2017-05-26

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(0)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8=N-OR9, CR8=N-NR10R11, CR8=NR12 or CR8=N-ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2NR13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said heterocyclic ring are independently optionally substituted by C1-C3alkyl, F; R8 is H, CH3 or C2H5; R9: H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R10 and R11 are each independently H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl;i or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with C1-C3 alkyl; R12 is C1-C3 alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)-C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R13 and R14 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6Cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R15; R15 is C1-C6alkyl optionally substituted with halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR16, NR17R18, C=NR19, or with a tetrazole group which is optionally substituted with C1-C3alkyl; or a heteroaryl ring which is optionally substituted with F, wherein the at least one heteroatom of said heteroaryl ring is nitrogen; R16 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR17R18, or with a heteroaryl ring, wherein the at least one heteroatom of said heteroaryl ring is nitrogen, and wherein preferably said heteroaryl ring is selected from pyrrolidine, piperidine, piperazine, morpholine, pyrrole, and imidazole, wherein nitrogen atom is directly bound to C1-C4 alkyl; R17 and R18 are each independently H or C1-C4alkyl optionally substituted with ONO, ONO2; R19 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6Cycloalkyl; and their use in methods of treating or preventing a disease alleviated by inhibition of PDE-5 in a human or in a non-human mammal.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐、溶剂或水合物，其中R1是C1-C3烷基，可选择地取代为F，C3-C6环烷基，C1-C3烷氧基；X代表键或C1-C3烷基，可选择地取代为OH，ONO，ONO2；R2是H，OH，ONO，ONO2，C（O）OH，C（O）OC1-C3烷基，CHO，CN，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（0）N（R6）OR7，S（O0-2）C1-C3烷基，CR8=N-OR9，CR8=N-NR10R11，CR8=NR12或CR8=N-ONO2；R3是C1-C6烷基，可选择地取代为F，OH，ONO，ONO2，C1-C3烷氧基，C3-C6环烷基；C3-C6环烷基，C2-C6烯基，C2-C6炔基；R4是C1-C6烷基，可选择地取代为C3-C6环烷基，C1-C6烷氧基，F，ONO，ONO2；C2-C6烯基，C2-C6炔基，C3-C6环烷基；R5是H，SO2NR13R14，NHSO2NR13R14；R6是H或C1-C3烷基；R7是H，C1-C3烷基，C1-C3烷氧基，C1-C3烷基取代苯基，苄基或杂环戒指，其中所述苯基，苄基或所述杂环戒指可选择地取代为C1-C3烷基，F；R8是H，CH3或C2H5；R9：H，C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3烷基，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；R10和R11各自独立地是H，C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；或与它们连接的氮原子一起形成杂环戒指，其中优选地所述杂环戒指选自氮杂环丙烷，氮杂环戊烷，吡咯烷，哌啶，吗啉，哌嗪和同哌嗪，其中所述杂环戒指可选择地取代为C1-C3烷基；R12是C1-C3烷基，可选择地取代为OH，ONO，ONO2，CN，COOH，COOC1-C3烷基，C1-C3烷氧基，OC（O）H，OC（O）-C1-C3烷基，C（O）N（R6）OR7，OC1-C3烷基烯基-C（O）OH，OC1-C3烷基烯基-C（O）OC1-C3烷基，OC1-C3烷基烯基-C（O）N（R6）OR7，S（O0-2）C1-C3烷基；R13和R14各自独立地是H或C1-C6烷基，可选择地取代为F，OH，ONO，ONO2，COOH，C1-C3烷氧基，C3-C6环烷基；或与它们连接的氮原子一起形成杂环戒指，其中优选地所述杂环戒指选自氮杂环丙烷，氮杂环戊烷，吡咯烷，哌啶，吗啉，哌嗪，2,5-二氮杂双环[2,2,1]庚烷和3,7-二氮杂双环[3,3,0]辛烷，其中所述杂环戒指可选择地取代为R15；R15是C1-C6烷基，可选择地取代为卤素，OH，ONO，ONO2，C1-C3烷氧基，C1-C3卤代烷氧基，COOR16，NR17R18，C=NR19，或与一个四唑基团取代，该四唑基团可选择地取代为C1-C3烷基；或一个杂芳环，可选择地取代为F，其中所述杂芳环的至少一个杂原子是氮；R16是H，或C1-C4烷基，可选择地取代为F，OH，ONO，ONO2，NR17R18，或与一个杂芳环取代，其中所述杂芳环的至少一个杂原子是氮，优选地所述杂芳环选自吡咯烷，哌啶，哌嗪，吗啉，吡咯，咪唑，其中氮原子直接连接到C1-C4烷基；R17和R18各自独立地是H或C1-C4烷基，可选择地取代为ONO，ONO2；R19是C1-C4烷基，可选择地取代为F，ONO，ONO2；C3-C6环烷基；以及它们在治疗或预防人类或非人类哺乳动物中通过抑制PDE-5缓解的疾病的方法中的使用。